Is Humacyte Stock a Good Investment?
Humacyte Investment Advice | HUMAW |
- Examine Humacyte's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Humacyte's leadership team and their track record. Good management can help Humacyte navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Humacyte's business and its evolving consumer preferences.
- Compare Humacyte's performance and market position to its competitors. Analyze how Humacyte is positioned in terms of product offerings, innovation, and market share.
- Check if Humacyte pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Humacyte's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Humacyte stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Humacyte is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Humacyte Stock
Researching Humacyte's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 3.16. Humacyte had not issued any dividends in recent years.
To determine if Humacyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Humacyte's research are outlined below:
| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte may become a speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Humacyte generates negative cash flow from operations | |
| Latest headline from news.google.com: HUMACYTE, INC. INVESTOR ALERT Investors - GlobeNewswire |
Humacyte's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
Determining Humacyte's profitability involves analyzing its financial statements and using various financial metrics to determine if Humacyte is a good buy. For example, gross profit margin measures Humacyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Humacyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Humacyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Humacyte. Check Humacyte's Beneish M Score to see the likelihood of Humacyte's management manipulating its earnings.
Evaluate Humacyte's management efficiency
The company has return on total asset (ROA) of (0.5323) % which means that it has lost $0.5323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.5081) %, meaning that it generated substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.96 in 2024. At this time, Humacyte's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 46.6 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.82).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.13 | 0.14 | |
| Tangible Book Value Per Share | 0.13 | 0.14 | |
| Enterprise Value Over EBITDA | (2.81) | (2.67) | |
| Price Book Value Ratio | 21.68 | 22.77 | |
| Enterprise Value Multiple | (2.81) | (2.67) | |
| Price Fair Value | 21.68 | 22.77 | |
| Enterprise Value | 271.4 M | 284.9 M |
Evaluating the management effectiveness of Humacyte allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Humacyte Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.466 |
Basic technical analysis of Humacyte Stock
As of the 23rd of November, Humacyte retains the Market Risk Adjusted Performance of (0.07), risk adjusted performance of 0.0029, and Standard Deviation of 7.05. Humacyte technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Humacyte variance and potential upside to decide if Humacyte is priced fairly, providing market reflects its last-minute price of 1.69 per share. Please also validate Humacyte jensen alpha, which is currently at (0.17) to confirm the company can sustain itself at a future point.Humacyte's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Humacyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Humacyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Humacyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Niklason Laura E over three months ago Disposition of 2625000 shares by Niklason Laura E of Humacyte at 2.75 subject to Rule 16b-3 | ||
Heather Prichard over three months ago Acquisition by Heather Prichard of 136000 shares of Humacyte subject to Rule 16b-3 | ||
Wallace Max N. over six months ago Disposition of 6564 shares by Wallace Max N. of Humacyte at 1.19 subject to Rule 16b-3 | ||
Heather Prichard over six months ago Disposition of 6564 shares by Heather Prichard of Humacyte subject to Rule 16b-3 |
Understand Humacyte's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Humacyte's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0029 | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 4.98 | |||
| Coefficient Of Variation | (12,673) | |||
| Standard Deviation | 7.05 | |||
| Variance | 49.73 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 44.32 | |||
| Value At Risk | (10.05) | |||
| Potential Upside | 12.82 | |||
| Skewness | (0.27) | |||
| Kurtosis | 2.44 |
| Risk Adjusted Performance | 0.0029 | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 4.98 | |||
| Coefficient Of Variation | (12,673) | |||
| Standard Deviation | 7.05 | |||
| Variance | 49.73 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 44.32 | |||
| Value At Risk | (10.05) | |||
| Potential Upside | 12.82 | |||
| Skewness | (0.27) | |||
| Kurtosis | 2.44 |
Consider Humacyte's intraday indicators
Humacyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Humacyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Humacyte time-series forecasting models is one of many Humacyte's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Humacyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Humacyte Stock media impact
Far too much social signal, news, headlines, and media speculation about Humacyte that are available to investors today. That information is available publicly through Humacyte media outlets and privately through word of mouth or via Humacyte internal channels. However, regardless of the origin, that massive amount of Humacyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Humacyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Humacyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Humacyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Humacyte alpha.
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| MS MS | Chief Officer | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Kiernan MD | Chief Officer | Profile | |
| Dale Sander | Chief CFO | Profile | |
| William Scheessele | Chief Officer | Profile |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.